NEW real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) do not increase the risk of acute pancreatitis and may be associated with improved outcomes in patients with Type 2 diabetes who develop the condition.
GLP-1 receptor agonists, including widely used agents such as semaglutide, liraglutide, dulaglutide, and tirzepatide, have transformed the management of Type 2 diabetes and obesity. However, concerns have persisted regarding their potential association with pancreatitis.
Large-Scale Real-World Analysis
In this retrospective cohort study, researchers analysed data from more than 740,000 patients with Type 2 diabetes using the TriNetX Research Network. After propensity score matching, over 20,000 patients receiving GLP-1 receptor agonists were compared with a matched cohort not using these medications.
To minimise confounding, known causes of pancreatitis such as alcohol use, biliary disease, and hypertriglyceridaemia were excluded.
No Increased Risk of Pancreatitis
The analysis found no evidence that GLP-1 receptor agonist use increased the risk of developing acute pancreatitis. In fact, there was a trend toward a lower risk, although this did not reach statistical significance.
These findings help address ongoing safety concerns surrounding this widely prescribed class of medications.
Reduced Complications and Mortality
Among patients who did develop acute pancreatitis, those receiving GLP-1 receptor agonists had significantly better outcomes. The GLP-1 group showed markedly lower risks of severe complications, including sepsis, acute kidney injury, shock, and the need for mechanical ventilation.
They were also less likely to require parenteral nutrition and had a substantially lower risk of developing complicated pancreatitis overall.
Importantly, all-cause mortality was significantly reduced in patients treated with GLP-1 receptor agonists compared with those not receiving these therapies.
Implications for Clinical Practice
These findings suggest that GLP-1 receptor agonists are not only safe from a pancreatitis risk perspective but may also confer protective effects in patients who develop acute pancreatitis.
The mechanisms underlying these benefits remain unclear but may relate to metabolic improvements, anti-inflammatory effects, or better overall disease control.
Looking Ahead
As a retrospective observational study, the findings cannot establish causality, and prospective studies will be needed to confirm these associations and explore underlying mechanisms.
Nonetheless, the results provide reassuring evidence for clinicians and patients, supporting the continued use of GLP-1 receptor agonists in Type 2 diabetes without added concern for pancreatitis risk, and raising the possibility of improved outcomes in those who do develop the condition.
Reference
Nieto LM et al. Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis. Am J Gastroenterol. 2026;121(2):424-31.
Featured Image: Patrick Bay Damsted on Adobe Stock
